Fernández, José J. http://orcid.org/0000-0001-7552-0076
Mancebo, Cristina http://orcid.org/0000-0002-0175-1493
Garcinuño, Sonsoles http://orcid.org/0000-0001-8108-0839
March, Gabriel
Alvarez, Yolanda http://orcid.org/0000-0002-4851-8277
Alonso, Sara
Inglada, Luis
Blanco, Jesús
Orduña, Antonio
Montero, Olimpio
Sandoval, Tito A. http://orcid.org/0000-0003-2705-5282
Cubillos-Ruiz, Juan R.
Bustamante-Munguira, Elena
Fernández, Nieves http://orcid.org/0000-0002-9141-3956
Crespo, Mariano Sánchez http://orcid.org/0000-0002-6149-154X
Funding for this research was provided by:
Ministerio de Economía y Competitividad (PID2020-113751RB-I00, SAF2017-83079-R)
Ministerio de Ciencia y Tecnología, Gobierno de la Provincia de Córdoba (PID2020-113751RB-I00)
Consejería de Educación, Junta de Castilla y León (VA175P20)
Article History
Received: 24 July 2023
Revised: 4 December 2023
Accepted: 7 December 2023
First Online: 25 December 2023
Competing interests
: JRCR holds patents on the use of IRE1α modulators for the treatment of disease and serves as scientific consultant for Immagene B.V., NextRNA Therapeutics, Inc., and Autoimmunity Biologic Solutions, Inc. All other authors declare no potential conflicts of interest.
: The clinical part of the study was approved by the Ethics Committee of Area de Salud Valladolid Este (ref. PI-GR-20-2011 COVID). For in vitro experiments, MDDCs were obtained from human mononuclear cells collected from pooled buffy coats of healthy donors provided by Centro de Hemoterapia y Hemodonación de Castilla y León Biobank. The study was approved by the Bioethical Committee of the Spanish Council of Research (CSIC) and the written informed consent of all healthy donors was obtained at Centro de Hemoterapia y Hemodonación de Castilla y León Biobank. The process is documented by the Biobank authority according to the specific Spanish regulations. The ethics committee approved this procedure before starting the study.